Peer-reviewedCC BYJAAD case reports
Remibrutinib as a novel therapy for refractory granuloma annulare.
- 1University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.
- 2East Valley Dermatology Center, Chandler, Arizona.
Related
- Vehicle Optimization of Topical Clobetasol Propionate in Disseminated Granuloma Annulare: Clinical Insights From Two Cases
- 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case
- Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity
- Complete transcatheter closure of residual aortopulmonary window in an elderly patient allowing optimization of refractory pulmonary arterial hypertension therapy.
BibTeX
@article{chinyere2026remibrutinib,
title = {{Remibrutinib as a novel therapy for refractory granuloma annulare.}},
author = {Tyler C Chinyere and Ryan Falsey},
journal = {JAAD case reports},
year = {2026},
month = sep,
doi = {10.1016/j.jdcr.2026.09.016},
url = {https://europepmc.org/article/MED/42904203},
note = {CC BY},
}
RIS
TY - JOUR
TI - Remibrutinib as a novel therapy for refractory granuloma annulare.
AU - Tyler C Chinyere
AU - Ryan Falsey
PY - 2026
DA - 2026/09/16
JO - JAAD case reports
DO - 10.1016/j.jdcr.2026.09.016
UR - https://europepmc.org/article/MED/42904203
SN - 2352-5126
ER -